Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

The voting results can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers in prioritising areas for future research. Diagnostic and treatment decisions should always be individualised on the basis of patient and cancer characteristics, and should incorporate current and emerging clinical evidence, guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2024 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials.

Authors

Institutions

Publication Details

Journal
European Urology
Published
2024-10-11
DOI
https://doi.org/10.1016/j.eururo.2024.09.017
Citations
98
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
39.80

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Gerhardt Attard, Mouna Ayadi, Mika Matikainen, Dana E. Rathkopf et al.
98 citations
European Urology
Prostate Cancer Treatment and Research
39.80
article

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Gerhardt Attard, Mouna Ayadi, Mika Matikainen, Dana E. Rathkopf, Christopher J. Sweeney, Maria Teresa Bourlon, Darren M.C. Poon, Shingai B.A. Mutambirwa, Cora Nanette Sternberg, Kim N. Chi, Karol Axcrona, Ray McDermott, Ken Herrmann, Eric Jay Small, Karim S. Fizazi, Camilla Thellenberg‐Karlsson, Silke Gillessen, Fabio Turco, Pierre Blanchard, Charles J. Ryan, Edward M. Schaeffer, Paul Linh Nguyen, Anders Bjartell, Axel S. Merseburger, Michael J. Morris, Iwona Skoneczna, Emmanuel S. Antonarakis, Felix Yi-Chung Feng, Bertrand F. TOMBAL, Jochen Walz, Ana Maria Aparicio, Nicholas David James, Mary‐Ellen Taplin, Daniel Castellano, Orazio Caffo, Thomas Zilli, Diogo Assed Bastos, Danny Rabah, Derya Tilki, Stacy Loeb, Alberto Briganti, Raja B. Khauli, Ignacio Durán, Niven Mehra, Joaquı́n Mateo, Nima Sharifi, Andrew J. Armstrong, Neha Vapiwala, Raphaële Renard‐Penna, Maha Hussain, Aurelius Omlin, Anwar R. Padhani, A. Zapatero, Omolara Fatiregun, Claire L. Vale, Heather H. Cheng, Daniel J. George, Himisha Beltran, Jason A. Efstathiou, Robert J. Jones, Joe M. O’Sullivan, Daniel Keizman, Vedang Murthy, Juan Pablo Sade, Caroline S. Clarke, Susan Halabi, Deborah Mukherji, Fred Saad, Barbara Alicja Jereczek‐Fossa, Valérie Fonteyne, Peter C.C. Fong, R. Kanesvaran, Louise Emmett, Rana R. McKay, Consuelo Buttigliero, Howard R. Soule, Hind M’rabti, Kosj Yamoah, Stefano Fanti, Muhammad Bulbul, Martin Gleave, Michael S. Hofman, Shahneen Kaur Sandhu, Colin C. Pritchard, Ian D. Davis, Noel W. Clarke, David Matheson, Gwénaëlle Gravis, Yüksel Ürün, Alicia Katherine Morgans, Gero Kramer, Johann Sebastian De Bono, Thomas A. Hope, Howard I. Scher, Daniel Eidelberg Spratt, Elena Castro, William Oh, Nicola Fossati, Eleni Efstathiou, Piet Ost, Lisa Glen Horvath, Evan Y. Yu, Anthony M. Joshua, Hiroji Uemura, Neal D. Shore, Neeraj Agarwal, Matthew R. Smith, Declan G. Murphy, Dingwei Ye, Maria De Santis, Brandon A. Mahal, Daniel Heinrich, Levent N. Türkeri, Oliver A. Sartor, Chris Parker, Onyeanunam Ngozi Ekeke, Sandy Srinivas, Robert E. Reiter, Tamer I H El Nahas, Hiroyoshi Suzuki, Fernando Cotait Maluf
article en
98 citations

Abstract

The voting results can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers in prioritising areas for future research. Diagnostic and treatment decisions should always be individualised on the basis of patient and cancer characteristics, and should incorporate current and emerging clinical evidence, guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2024 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials.

European UrologyVol. 87(2)
Northwestern University (US), University of Wolverhampton (GB), Queen's University Belfast (GB), Oslo University Hospital (NO), Brigham and Women's Hospital (US), Houston Methodist (US), Toho University (JP), Cliniques Universitaires Saint-Luc (BE), Memorial Sloan Kettering Cancer Center (US), NewYork–Presbyterian Hospital (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), University of British Columbia (CA), Institute of Cancer Research (GB), Cairo University (EG), University of Miami (US), Radboud University Nijmegen (NL), Ankara University (TR), University of Auckland (NZ), Vita-Salute San Raffaele University (IT), Inserm (FR), Universität Hamburg (DE), University of California, Los Angeles (US), Duke University (US), Palo Alto University (US), Chinese University of Hong Kong (HK), University of California, San Francisco (US), Homi Bhabha National Institute (IN), University of Washington (US), University of Zurich (CH), Cornell University (US), Aix-Marseille Université (FR), University of Utah (US), Innlandet Hospital Trust (NO), Université Paris-Saclay (FR), University of Port Harcourt Teaching Hospital (NG), Tel Aviv Sourasky Medical Center (IL), Akershus University Hospital (NO), Hospital Israelita Albert Einstein (BR), Helsinki University Hospital (FI), Peter MacCallum Cancer Centre (AU), Prostate Cancer Foundation (US), King Faisal Specialist Hospital & Research Centre (SA), New York Hospital Queens (US), Huntsman Cancer Institute (US), Ghent University Hospital (BE), Auckland City Hospital (NZ), Institut Gustave Roussy (FR), Yokohama City University Medical Center (JP), Sefako Makgatho Health Sciences University (ZA), Sydney Hospital (AU), Radboud University Medical Center (NL), Moffitt Cancer Center (US), Acıbadem University (TR), Sorbonne Université (FR), NYU Langone Health (US), St Vincent's Hospital Sydney (AU), Massachusetts General Hospital (US), Ospedale Santa Chiara (IT), Fred Hutch Cancer Center (US), Institut Salah-Azaïz (TN), MRC Clinical Trials Unit at UCL (GB), Fudan University Shanghai Cancer Center (CN), Chris O’Brien Lifehouse (AU), Ente Ospedaliero Cantonale (CH), Presbyterian Hospital (US), Assistance Publique – Hôpitaux de Paris (FR), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX), Eastern Health (AU), St Vincent’s Private Hospital Sydney (AU), Hong Kong Sanatorium and Hospital (HK), Hospital Universitario 12 De Octubre (ES), Cancer Trials Ireland (IE), American University of Beirut Medical Center (LB), Mount Vernon Cancer Centre (GB), Martini-Klinik (DE), Salford Royal Hospital (GB), University Hospital Schleswig-Holstein (DE), Instituto de Investigación Marqués de Valdecilla (ES), Beneficência Portuguesa de São Paulo (BR), Dana-Farber Cancer Institute (US), Lagos State University Teaching Hospital (NG), University Hospitals Seidman Cancer Center (US), Essen University Hospital (DE), Royal Marsden Hospital (GB), Pitié-Salpêtrière Hospital (FR), Istituto delle Scienze Neurologiche di Bologna (IT), St Vincent's Clinic (AU), Mayo Clinic in Arizona (US), Toho University Medical Center Sakura Hospital (JP), Instituto Alexander Fleming (AR), Duke Medical Center (US), Tisch Hospital (US), Vall d'Hebron Hospital Universitari (ES), Hospital Universitario de La Princesa (ES), IRCCS Ospedale San Raffaele (IT), University of Minnesota Medical Center (US), Iridium Kankernetwerk (BE), National Cancer Centre Singapore (SG), Stanford Medicine (US), Skåne University Hospital (SE), Centre for Cancer Biology (AU), Centre Hospitalier de l’Université de Montréal (CA), Mayo Clinic in Florida (US), CRUK Lung Cancer Centre of Excellence (GB), Hospital Sírio-Libanês (BR), Institut Paoli-Calmettes (FR), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), GastroZentrum Hirslanden Zürich (CH), Institut National d'Oncologie (MA), The Kinghorn Cancer Centre (AU), Sylvester Comprehensive Cancer Center (US), Dana-Farber Brigham Cancer Center (US), Carolina Urologic Research Center (US), UCSF Helen Diller Family Comprehensive Cancer Center (US), Weill Cornell Medicine (US), Vall d'Hebron Institute of Oncology (ES), Onco-Urologie Prédictive (FR), University College London (GB), University of Turin (IT), The University of Adelaide (AU), Università della Svizzera italiana (CH), European Institute of Oncology (IT), University of Duisburg-Essen (DE), Medical University of Vienna (AT), Charité - Universitätsmedizin Berlin (DE), University of Glasgow (GB), University of Pennsylvania (US), Yokohama City University (JP), Umeå University (SE), University of Lübeck (DE), Stanford University (US), American University of Beirut (LB)
Prostate Cancer Foundation, Movember Foundation, Royal Marsden NHS Foundation Trust, Peter MacCallum Foundation, Medical Research Council, National Health and Medical Research Council
Good health and well-being
Openalex Percentile: Top 0%
Prostate Cancer Treatment and Research
39.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.